A phase II evaluation of irofulven (IND 55804, NSC 683863) in the treatment of recurrent or persistent platinum-sensitive ovarian or primary peritoneal cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Irofulven (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2010 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University record no. GOG0146O).
- 23 Jul 2008 The completion date for this trial has been amended from Aug 2004 to Jul 2008.
- 12 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.